BMS Focuses On Driving Future Growth As Revlimid Generic Launches Near

Opdivo, Eliquis Rise From Year-Ago Quarter, But Down From Q2

 
• By Mandy Jackson

New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.

Business investment growth concept with abstract arrows on building
Total third quarter revenue of $11.6bn was up 10% from Q3 2020 • Source: Alamy

More from New Products

More from Scrip